1[1]Dialysis and transplantation registration group,Chinese society of nephrology.The report about the regiration of dialysis and transportation in China 1999.Chin J Nephrol,2001,17:77-78. 被引量：1
2[2]Hou FF,Zhang Xun,Zhang GH,et al,Efficacy and safety of Benazepril for advanced chronic renal insufficiency.New Engl J Med,2006,354:131-140. 被引量：1
3[3]Dahlof B,Devereux RB,Kjeldsen SE,et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol.Lancet,2002,359:995-1003. 被引量：1
4[4]Stoschitzky K,Koshucharova G,Zweiker R,et al.Differing betablocking effect s of carvedilol and metoprolol.Eur J Heart Fail,2001,3:343-349. 被引量：1
5[5]Bakris GL,Fonseca V,Katholi RE,et al.Differential effects of ?-Blockers on albuminuria in patients with type 2 diabetes.Hypertension,2005,46:1309-1315. 被引量：1
7[7]Garg JP,Bakris GL.Microalbuminuria:marker of vascular dysfunction,risk factor for cardiovascular disease.Vasc Med,2002,7:35-43. 被引量：1
8[8]Cheng J,Kamiya K,Kodama I.Carvedilol:molecular and cellular basis for its multifaceted therapeutic potential.Cardiovasc Drug Rev,2001; 19:152-171. 被引量：1
9[9]Singh D,Chander V,Chopra K.Carvedilol,an antihypertensive drug with antioxidant properties,protects against glycerol-induced acute renal failure.Am J Nephrol,2003,23:415-421. 被引量：1
二级参考文献6
1[1]Fassbinder W,Quarder O,Waltz A.Treatment with carvedilol is associated with a significant reduction in microalbuminuria:a multicentre randomized study[J].Int J Clin Pract,1999,53(7):519-522. 被引量：1
2[2]Agrawal B,Abraham WT,Tsvetkova T,et al.Carvedilol improves renal hemodynamics in patients with chronic heart failure[J].J Cardiac Failure,1998,4(Suppl.1):Abstract 5 . 被引量：1
3[3]Yue T-L,Mckenna PJ,Lysko PG,et al.Carvedilol,a new antihypertensive,prevents oxidation of human low density lipoprotein by macrophages and copper[J].Atherosclerosis ,1992,97:209-216. 被引量：1
4[4]Agrawal B,Wolf K,Berger A.Effect of various antihypertensive treatments on the progress of microalbuminuria in non-diabetic hypertensives.Vienna:European Dialysis and Transplant Association,1994.Abstract 被引量：1
5[5]McTavish D,Campoli-Richards D,Sorkin EM.Carvedilol:A review of its pharmacodynamic and pharmacokinetic properties,and therapeutic efficacy[J].Drugs,1993,45(2):232-258. 被引量：1
6[6]Toshio O,Masao I,Yuichiro G,et al.The effect of low dose carvedilol on circadian variation of blood pressure in patient with essential hypertension[J].J Cardiovasc Pharmacol,1987,10(Suppl.11):108-112. 被引量：1
